Biotest AG: Biotest completes recruitment in Phase IIb study (TREAT 2b) of Tregalizumab (BT-061) in patients with rheumatoid arthritis
Biotest AG / Key word(s): Research Update / Biotest completes recruitment in Phase IIb study (TREAT 2b) - Biotest's largest and most complex clinical study is running according to plan - Patient recruitment completed. More than 300 patients enrolled within the past ten months
TREAT 2b study is a double blind, randomised and placebo-controlled trial with four treatment groups, evaluating the efficacy and safety of tregalizumab "Biotest is committed to develop and market new medications in areas of high medical need. The unique mode of action of BT-061 will hopefully open a new therapeutic option for patients with rheumatoid arthritis and other autoimmune diseases with high efficacy and good quality of life. This new drug is developed in close cooperation with medical and scientific key opinion leaders worldwide," said Prof Gregor Schulz, CEO of Biotest AG. Key data from the main part of TREAT 2b will be the basis for start of Phase III clinical development. About Tregalizumab (BT-061) About rheumatoid arthritis Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de Securities' ID No., ISIN ordinary shares: 522720, DE0005227201 09.09.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and www.dgap.de |
Language: | English | |
Company: | Biotest AG | |
Landsteinerstraße 5 | ||
63303 Dreieich | ||
Germany | ||
Phone: | 0 61 03 - 8 01-0 | |
Fax: | 0 61 03 - 8 01-150 | |
E-mail: | investor_relations@biotest.de | |
Internet: | http://www.biotest.de | |
ISIN: | DE0005227235, DE0005227201 | |
WKN: | 522723, 522720 | |
Indices: | SDAX | |
Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart | |
End of News | DGAP News-Service |
286231 09.09.2014 |